제품 수집
제품 세부정보
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Human BCMA (Luc) Jurkat Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human BCMA (Uniprot: Q02223-1). When stimulated with human APRIL or BAFF protein, receptor-mediated signaling can drive NF-κB-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.
Application
• Screen for neutralizing antibodies blocking the stimulation of human APRIL or BAFF protein
Growth Properties
Suspension
Selection Marker
Puromycin (2 μg/mL) + G418 (200 μg/mL)
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Application
Inhibition of human APRIL protein-induced reporter activity by anti-human APRIL neutralizing antibody.
The Human BCMA (Luc) Jurkat Reporter Cell was incubated with serial dilutions of antibodies in the presence of human APRIL protein (Cat. No. APL-H52D1) with a final concentration of 0.05 μg/mL. The EC50 of anti-human APRIL neutralizing antibody (Sibeprenlimab) is approximately 0.06 μg/mL.Protocol
Inhibition of human BAFF protein-induced reporter activity by anti-human BAFF neutralizing antibody.
The Human BCMA (Luc) Jurkat Reporter Cell was incubated with serial dilutions of antibodies in the presence of human BAFF protein (Cat. No. BAF-H52D4) with a final concentration of 1 μg/mL. The EC50 of anti-human BAFF neutralizing antibody (Belimumab) is approximately 0.32 μg/mL.Protocol
Inhibition of human APRIL protein-induced reporter activity by anti-human BCMA neutralizing antibody.
The Human BCMA (Luc) Jurkat Reporter Cell was incubated with serial dilutions of antibodies in the presence of human APRIL protein (Cat. No. APL-H52D1) with a final concentration of 0.05 μg/mL. The EC50 of anti-human BCMA neutralizing antibody (Belantamab) is approximately 0.41 μg/mL.Protocol
Inhibition of human BAFF protein-induced reporter activity by anti-human BCMA neutralizing antibody.
The Human BCMA (Luc) Jurkat Reporter Cell was incubated with serial dilutions of antibodies in the presence of human BAFF protein (Cat. No. BAF-H52D4) with a final concentration of 1 μg/mL. The EC50 of anti-human BCMA neutralizing antibody (Belantamab) is approximately 0.12 μg/mL.Protocol
Signaling Bioassay
Response to human APRIL protein (RLU).
The Human BCMA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of human APRIL protein (Cat. No. APL-H52D1). The max induction fold was approximately 141.73.Protocol
Response to human APRIL protein (FOLD).
The Human BCMA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of human APRIL protein (Cat. No. APL-H52D1). The max induction fold was approximately 141.73Protocol
Response to human BAFF protein (RLU).
The Human BCMA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of human BAFF protein (Cat. No. BAF-H52D4). The max induction fold was approximately 133.55.Protocol
Response to human BAFF protein (FOLD).
The Human BCMA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of human BAFF protein (Cat. No. BAF-H52D4). The max induction fold was approximately 133.55.Protocol
사용자 리뷰 댓글 남기기
중요 성명
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
프론티어 진행
의약품 개발 진행- 영어 이름：
B-cell maturation protein
- 카테고리：
- 상장 의약품 수：
8 상세
- 임상 의약품 수：
145 상세
- 최고 개발 단계：
Approved
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
